Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | TDP2 | O95551 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126280 | 0.85 | KMT2A (0.62) | KDM4EKMT2AMEN1APAF1TDP2 | |
| SCHEMBL16861478 | 0.83 | KMT2A (0.51) | KDM4EKMT2AMEN1APAF1TDP2 | |
| SCHEMBL31071774 | 0.82 | KMT2A (0.50) | KDM4EKMT2AMEN1APAF1TDP2 | |
| SCHEMBL15053947 | 0.81 | KDM4E (0.61) | KDM4EKMT2AMEN1APAF1TDP2 | |
| SCHEMBL29448814 | 0.80 | KDM4E (0.59) | KDM4EPARP1RPS6KB1L3MBTL1HTT | |
| SCHEMBL27767795 | 0.80 | KDM4E (0.64) | KDM4EPARP1RPS6KB1L3MBTL1AURKA | |
| SCHEMBL27930130 | 0.80 | KDM4E (0.59) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL23360051 | 0.80 | KMT2A (0.53) | KDM4EKMT2AMEN1APAF1TDP2 | |
| SCHEMBL31056854 | 0.80 | KDM4E (0.62) | KDM4EKMT2AMEN1APAF1TDP2 | |
| SCHEMBL23359872 | 0.80 | KMT2A (0.47) | KDM4EKMT2AMEN1APAF1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
| EP-4288431-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167682-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-11 | — | — | WO | disclosed |
| WO-2021048200-A1 | NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| US-10457662-B2 | Substituted amides for treating and preventing cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180282296-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282296-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | NNT, NQO1, NAMPT | KDM4E 2863/4885KMT2A 1353/4885MEN1 1017/4885 |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | KDM4E 411/4885KMT2A 697/4885MEN1 3256/4885 |
| US-10457662-B2 | Substituted amides for treating and preventing cancer | NQO1, NNT, SIRT1 | KDM4E 1342/4885KMT2A 584/4885MEN1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.